| 摘要 |
PROBLEM TO BE SOLVED: To provide prostate cancer therapeutic agents for the treatment of metastatic stage prostate cancer or for the delay or prevention of progression of localized or locally advanced prostate cancer into metastatic stage, the agents being gonadotropic hormone releasing hormone receptor antagonists.SOLUTION: A composition for treating metastatic stage prostate cancer in a subject contains degarelix (D-alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-[[[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]-L phenylalanyl-4-[(aminocarbonyl)amino]-D-phenylalanyl-L leucyl N6-(1-methylethyl)-L-lysyl-L-prolyl). A method is provided for administering to a subject whose normal value of serum alkaline phosphatase is 150 IU/L or more, e.g. 160 IU/L or more, particularly 200 IU/L or more.SELECTED DRAWING: Figure 1 |
